Share Name Share Symbol Market Type Share ISIN Share Description
Immupharma Plc LSE:IMM London Ordinary Share GB0033711010 ORD 10P
  Price Change % Change Share Price Shares Traded Last Trade
  1.00 4.76% 22.00 1,691,095 16:35:18
Bid Price Offer Price High Price Low Price Open Price
21.10 22.90 22.95 21.00 21.05
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.08 -7.96 -5.19 37
Last Trade Time Trade Type Trade Size Trade Price Currency
16:29:16 O 7,696 21.226 GBX

Immupharma (IMM) Latest News

More Immupharma News
Immupharma Takeover Rumours

Immupharma (IMM) Discussions and Chat

Immupharma (IMM) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2019-12-06 16:29:1721.237,6961,633.55O
2019-12-06 16:27:5522.139,0121,993.91O
2019-12-06 16:27:1621.273,232687.41O
2019-12-06 16:27:1522.858,7301,994.81AT
2019-12-06 16:25:1922.208,0571,788.81O
View all Immupharma trades in real-time

Immupharma (IMM) Top Chat Posts

Immupharma Daily Update: Immupharma Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker IMM. The last closing price for Immupharma was 21p.
Immupharma Plc has a 4 week average price of 6.91p and a 12 week average price of 6.91p.
The 1 year high share price is 32p while the 1 year low share price is currently 6.91p.
There are currently 167,360,920 shares in issue and the average daily traded volume is 6,313,073 shares. The market capitalisation of Immupharma Plc is £36,819,402.40.
whatsthepoint: From LSE 2019-12-06 15:16:00Investment bank Life Sciences Division upgraded its share price target to 100p from 76p on the back of the recent deal with US speciality drugs group Avion PharmaceuticalsImmuPharma PLC - ImmuPharma s Lupuzor could be US blockbuster, says Life Sciences DivisionImmuPharma PLC's (LON:IMM) lupus candidate Lupuzor could become a US blockbuster by generating over US$1bn revenues per year, according to Life Sciences Division.The investment bank raised its target for the AIM-listed drug developer's share price to 100p from 76p on the back of the recent deal with US speciality drugs group Avion Pharmaceuticals.READ: ImmuPharma shoots up 300% after it inks US licensing deal for flagship drug LupuzorAvion will fund a new phase III trial, while Immupharma will also receive milestone payments and an agreed 17% royalty on sales.ImmuPharma has the potential to rack in annual royalties of up to US$170mln from the deal, according to the Life Sciences Division analysts.This deal is only exclusive to the US market, meaning ImmuPharma can look for other distribution partners in other geographies, such as Europe, where there is no need for a new trial given Avion's funding commitment.Further agreements will allow ImmuPharma to multiply income from Lupuzor with other royalties and milestone payments.According to Life Sciences Division, Lupuzor may get second or third place in the US market if rival AstraZeneca PLC's (LON:AZN) Anifrolumab gets a US licensing deal."Lupuzor with a 71.1% response rate in the anti-ds DNA auto antibody-positive patients, could also eventually be the product with the best overall response rate and safety profile in the market," LSD analysts added.Shares in ImmuPharma were trading 3% higher on Friday afternoon at the 21.6p.
njb67: Wig ?? What has that got to do with me? Prior to the announcement, the last time I posted on IMM was in June? Do you not check any of your facts before posting them? The share price then was more than double the low point for the year.
master rsi: Profit taking this morning? There was some after the day started, what I think happen Many investors, did not see the rise yesterday untill they reach home last night and took the opportunity to sell early this morning after over a Year waiting for the share to rise. As the price started to drift the shorters join in and took the share price further down, as all the MALICIOUS posts started to appear. Once all was done and settle the share price is bouncing back and so far so good as the share price is going to surpass yesterday close before long.
ny boy: Buying zone coming up, they will take this to test 34p (Lanstead) level Under the Lanstead deal, IMM will receive monthly payments from Lanstead for the shares that they have issued them. If the share price averages over the 34.667p benchmark price, IMM will make more than the £4.43m estimated. If the share price is at double that for the month, IMM receive double that month. Conversely, if the share is at half the benchmark price for the month, IMM receive half that month. Note this is not an equity line of credit. Lanstead have all the shares. There is no fresh dilution each month and Lanstead do not sell every month. Indeed they held back in selling IMM until they could place with new IIs wanting to buy in,
sclper: With hindsight that Lanstead deal was great. As the share price appreciates IMM receives a larger monthly payment. I think that RNS will lead to a 500% rise in the share price so the company will be very well funded for the foreseeable future
sicilian_kan: It has taken a little while for me to digest the deal, but the more I look at it the more I think it is structured well for IMM at this stage. The key here is that IMM has retained 100% of the commercialisation of the Rest of the World rights. It owns 100% of Europe, Asia etc. It retains 100% of Europe even though Avalon's Phase III trial will be including European patients! So IMM effectively has a free carry through phase 3 to up to 17% of the US market and 100% of Europe and the rest of the world. The numbers on the US up to 17% could be very tasty on their own. The numbers for IMM on the 100% in Europe and elsewhere could be huge. I don't want to say where the share price will go, and I'm not saying Lupuzor will succeed, but it is grossly undervalued as of today.
spawny100: Never mind last couple of years petroc - IMM share price is back to 2003 levels. Anyone who sees value at these prices needs to seriously analyse why imo.
the_merlion: Mind you Ham, you have done better trolling then Growth and Nobby today. Fair play to you, I am sure you will make those thousands of pounds you lost with a entry at 150 back in the day. I guess you are a little scared to punt in, as you now only have 25% or the original pot left to work, but that is your own stupid fault LMFAO. hamhamham1 - 01 May 2018 - 13:49:36 - 30009 of 30012 IMMUPHARMA - IN FINAL PHASE 3 LUPUS TRIAL TARGETING BLOCKBUSTER ($1bn+) REVENUES - IMM Personally i trust Panmures ability to calculate an asset price over the posters on here. hamhamham1 - 01 May 2018 - 13:21:59 - 30000 of 30012 IMMUPHARMA - IN FINAL PHASE 3 LUPUS TRIAL TARGETING BLOCKBUSTER ($1bn+) REVENUES - IMM IMHO. If the company's share price was sub 40p before all the hype of the p3 started (end 2016) with still then with all that hope ahead. Then after the bad p3 readout then I reckon half that is a more than generous share price. hamhamham1 - 01 May 2018 - 12:20:34 - 29991 of 30012 IMMUPHARMA - IN FINAL PHASE 3 LUPUS TRIAL TARGETING BLOCKBUSTER ($1bn+) REVENUES - IMM My money is still on it hitting the Panmure Gordon target of 22p. Time will tell. hamhamham1 - 01 May 2018 - 12:03:20 - 29987 of 30012 IMMUPHARMA - IN FINAL PHASE 3 LUPUS TRIAL TARGETING BLOCKBUSTER ($1bn+) REVENUES - IMM If I bought shares here now, I would be buying on the hope that something comes over the horizon which is not currently scheduled to happen. Is that investing or gambling? hamhamham1 - 01 May 2018 - 11:28:27 - 29980 of 30012 IMMUPHARMA - IN FINAL PHASE 3 LUPUS TRIAL TARGETING BLOCKBUSTER ($1bn+) REVENUES - IMM What's the odds for hit 28p then drop?
growthinvestor2001: spmc - I remember you making wild claims about IMM share price too - look how that worked out. Just keep it to yourself....try and stop ramping / pumping for just one minute yeah?
hamhamham1: Merlion. Look, research companies are money pits they dilute shares and raise money all day long. They suck up money and nearly always end up with nothing of value to show for it. IMM share price went up based upon an immenant good p3 readout and thus real saleable asset value. It failed by over x5 the target level p value. The 22p is based upon that and not some pi investor hopes.
Immupharma share price data is direct from the London Stock Exchange
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191207 03:33:52